NDVA:CA:TSV-Indiva Ltd (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.06

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

N/A

USD 0.10B
LOVE:CA Cannara Biotech Inc

-0.03 (-3.61%)

USD 0.08B
ZYUS:CA ZYUS Life Sciences Corporation

N/A

USD 0.07B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.05B
LSL:CA LSL Pharma Group Inc.

N/A

USD 0.04B
PCLO:CA Pharmacielo Ltd

-0.01 (-5.41%)

USD 0.03B
SBBC:CA Simply Better Brands Corp

N/A

USD 0.03B
ROMJ:CA Rubicon Organics Inc

+0.01 (+1.37%)

USD 0.02B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B
DHB:CA Delivra Health Brands Inc.

N/A

USD 0.01B

ETFs Containing NDVA:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -36.84% 24% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.84% 24% F 13% F
Trailing 12 Months  
Capital Gain -7.69% 75% C 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.69% 75% C 69% C-
Trailing 5 Years  
Capital Gain 27.98% 100% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.98% 100% F 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 24.55% 95% A 73% C
Dividend Return 24.55% 95% A 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 182.48% 14% F 12% F
Risk Adjusted Return 13.45% 86% B+ 60% D-
Market Capitalization 0.02B 64% D 64% D

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector